Dual inhibition: a novel promising pharmacological approach for different disease conditions
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
To overcome the problems associated with polypharmacy, which include medication non compliance, adverse drug reactions, drug–drug interactions and increased pill-burden, various strategies, such as sustained-release drugs and fixed-dose combination regimens (polypills), have been developed. Out of these, a novel and very much promising approach is the use of dual-action drugs. Amongst the dual-action drugs, there is a class of compounds known as dual inhibitors, which possess the dual inhibitory activity. The most common examples of dual inhibitors are rivastigmine, ladostigil, asenapine, phenserine, amitriptyline, clomipramine, doxepin and desipramine. This review article focuses on the conventional drugs used in different diseases which possess dual inhibition activity as well as those which are still in the preclinical/clinical phase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“loss of pleasure).([72]) 466 Journal of Pharmacy and Pharmacology 2011; 63: 459–471”
BackgroundMaira, S.-M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., Brachmann, S., Chène, P., De Pover, A., Schoemaker, K., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0017 · Cited by 1,134
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors
Castro, A., & Martinez, A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792985 · Cited by 207 · cited 1×
“The role of AChE in an early step during the development of the senile plaque has also been demonstrated.([58]) The incorporation of AChE into amyloid aggregates results in the modification of the biochemical properties of the enzyme, which include sensitivity to low pH, inhibition at high substrate concentrations and…”
BackgroundSelective COX-2 Inhibitors and Dual Acting Anti-inflammatory Drugs: Critical Remarks
Bertolini, A., Ottani, A., & Sandrini, M. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867024606650 · Cited by 158
Youdim, M. B. H., Fridkin, M., & Zheng, H. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.08.023 · Cited by 128 · cited 1×
“These compounds have shown iron-chelating and MAO-A and MAO-B selective brain inhibitory and neuroprotectiveantiapoptotic actions.([55]) In M30, the pharmacophore of brainpermeable iron chelator, VK-28, plus the MAO-inhibitory neuroprotective propargylamine moiety of rasagiline are N”
BackgroundGal, S., Fridkin, M., Amit, T., Zheng, H., & Youdim, M. B. H. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_68 · Cited by 58
Cited by
Palanisamy, C. P., Pei, J., Alugoju, P., Anthikapalli, N. V. A., Jayaraman, S., Veeraraghavan, V. P., Gopathy, S., Roy, J. R., Janaki, C. S., Thalamati, D., et al. (2023) · Theranostics · doi:10.7150/thno.83066 · Cited by 165
“Cortical projections to the nucleus basalis are strongly correlated with cholinergic input to limbic and paralimbic cortices [92].”
BackgroundMultitarget drugs of plants origin acting on Alzheimer’s disease
Russo, P., Frustaci, A., Del Bufalo, A., Fini, M., & Cesario, A. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320130008 · Cited by 88
Cuzzucoli Crucitti, G., Métifiot, M., Pescatori, L., Messore, A., Madia, V. N., Pupo, G., Saccoliti, F., Scipione, L., Tortorella, S., Esposito, F., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501799k · Cited by 81
Metadata
- Authors
- Patyar, S., Prakash, A., & Medhi, B.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-01
- Volume
- 63
- Issue
- 4
- Pages
- 459-471
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W1480192781
- Cited by
- 39
- References
- 6
- FWCI
- 1.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dual inhibition: a novel promising pharmacological approach for different disease conditions. https://app.cochat.ai/papers/10.1111/j.2042-7158.2010.01236.x
- The paper
- Patyar, S., Prakash, A., & Medhi, B. (2011). Dual inhibition: a novel promising pharmacological approach for different disease conditions. Journal of Pharmacy and Pharmacology. https://doi.org/10.1111/j.2042-7158.2010.01236.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.